Navigation Links
Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
Date:8/16/2012

ANN ARBOR, Mich. and PHOENIX, Ariz. As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

"We're thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes," says Jay Hess, M.D. Ph.D., M.H.S.A., chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. "IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision."

"Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens," says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. "We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients."

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

"Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan," notes Ora Pescovitz, M.D., CEO of the U-M Health System and U-M executive vice president for medical affairs. "Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients."


'/>"/>
Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related biology news :

1. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
2. Ultrasound idea: Prototype NIST/CU bioreactor evaluates engineered tissue while creating it
3. Creating energy from light and air - new research on biofuel cells
4. Gecko feet hold clues to creating bandages that stick when wet
5. The future of plant science - a technology perspective
6. The future of plant science a technology perspective
7. Is seaweed the future of biofuel?
8. Algae biofuels: the wave of the future
9. Researchers identify Achilles heel of dengue virus, target for future vaccines
10. Desert to Rainforest global classroom links future teachers, classrooms in Phoenix and Panama
11. New technologies for a blue future
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology: